Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study

被引：2

作者：

Long, Bo ^{[1
]}

Zhou, Huinian ^{[1
]}

Yu, Zeyuan ^{[1
]}

Zhu, Junmin ^{[1
]}

Yang, Hanteng ^{[1
]}

Huang, Zeping ^{[2
]}

Wei, Dengwen ^{[3
]}

Chen, Shigong ^{[1
]}

Yang, Xiaojun ^{[4
]}

Zhao, Xiaoning ^{[3
]}

Zhang, Wenjuan ^{[5
]}

Yan, Hong ^{[6
]}

Guan, Xiaoying ^{[6
]}

Li, Long ^{[1
]}

Zhang, Gengyuan ^{[1
]}

Yu, Hongwei ^{[1
]}

Che, Shengfu ^{[1
]}

Gao, Zhongti ^{[1
]}

Jiang, Xiangyan ^{[1
]}

Luo, Changjiang ^{[1
]}

Mao, Jie ^{[1
]}

Zhao, Da ^{[7
]}

Li, Yumin ^{[2
]}

Jiang, Zebin ^{[4
]}

Jiao, Zuoyi ^{[1
,8
]}

机构：

[1] Lanzhou Univ Second Hosp, Gen Surg Dept, Lanzhou, Peoples R China

[2] Lanzhou Univ Second Hosp, Oncol Surg Dept, Lanzhou, Peoples R China

[3] Sun Yat Sen Univ, Gastrointestinal Surg Dept, Canc Ctr, Gansu Prov Canc Hosp, Lanzhou, Peoples R China

[4] Gansu Prov Hosp, Gen Surg Dept, Lanzhou, Peoples R China

[5] Lanzhou Univ Second Hosp, Radiol Dept, Lanzhou, Peoples R China

[6] Lanzhou Univ Second Hosp, Pathol Dept, Lanzhou, Peoples R China

[7] Lanzhou Univ, Hosp 1, Oncol Dept, Lanzhou, Peoples R China

[8] Lanzhou Univ Second Hosp, Biobank Tumors Plateau Gansu Prov, Lanzhou, Peoples R China

来源：

MED | 2025年 / 6卷 / 03期

关键词：

GASTROESOPHAGEAL JUNCTION; OPEN-LABEL; REGULATORY T; CANCER; NIVOLUMAB; IPILIMUMAB; OXALIPLATIN; LEUCOVORIN; DOCETAXEL; FLUOROURACIL;

D O I：

10.1016/j.medj.2024.10.008

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Treatment with cadonilimab and chemotherapy has shown promise as a first-line treatment for gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. However, its application in neoadjuvant settings has not yet been documented. Methods: This multicenter, phase 2 trial (ChiCTR2200066893) was conducted at four hospitals across China. Treatment-naive patients with locally advanced G/GEJ adenocarcinoma (cT3/4, N+, M0) and who were human epidermal growth factor receptor 2 negative received 3-cycle or 4-cycle neoadjuvant treatment of cadonilimab plus FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy, followed by gastrectomy and 4-cycle adjuvant FLOT chemotherapy. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included major pathological response (MPR), overall response rate (ORR), disease control rate (DCR), R0 resection rate, downstaging rate, and safety. Findings: Between December 23, 2022, and December 15, 2023, 32 of 38 patients completed the scheduled treatment, achieving an R0 resection rate of 100% (32/32). The pCR rate was 21.1% (8/38, 90% confidence interval [CI]: 9.7-32.4), and the MPR rate was 44.7% (17/38, 90% CI: 30.9-58.5). Radiological evaluations were available for 28 of 38 patients by blinded independent central review. The ORR was 60.7% (17/28, 90% CI: 44.7-76.7), and the DCR was 100.0% (28/28, 90% CI: 100.0-100.0). Tumor downstaging occurred in 71.9% of patients (23/32), with consistent efficacy across all populations observed in the subgroup analysis. Grade 3 adverse events occurred in 31.6% of patients without severe safety issues. Conclusions: Neoadjuvant cadonilimab plus FLOT chemotherapy treatment exhibits promising efficacy with manageable toxicities in locally advanced G/GEJ adenocarcinoma, providing preliminary evidence for further investigation. Funding: This study was funded by Akeso Biopharma.

引用

页数：15

共 49 条

[1] Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].

Abdel-Rahman, Omar ;

Fouad, Mona .

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) :183-193

[2] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[3] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Hofheinz, Ralf D. ;

Pauligk, Claudia ;

Kopp, Hans-Georg ;

Haag, Georg Martin ;

Luley, Kim Barbara ;

Meiler, Johannes ;

Homann, Nils ;

Lorenzen, Sylvie ;

Schmalenberg, Harald ;

Probst, Stephan ;

Koenigsmann, Michael ;

Egger, Matthias ;

Prasnikar, Nicole ;

Caca, Karel ;

Trojan, Joerg ;

Martens, Uwe M. ;

Block, Andreas ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Clemens, Michael ;

Illerhaus, Gerald ;

Zirlik, Katja ;

Behringer, Dirk M. ;

Schmiegel, Wolff ;

Pohl, Michael ;

Heike, Michael ;

Ronellenfitsch, Ulrich ;

Schuler, Martin ;

Bechstein, Wolf O. ;

Koenigsrainer, Alfred ;

Gaiser, Timo ;

Schirmacher, Peter ;

Hozaeel, Wael ;

Reichart, Alexander ;

Goetze, Thorsten O. ;

Sievert, Mark ;

Jaeger, Elke ;

Moenig, Stefan ;

Tannapfel, Andrea .

LANCET ONCOLOGY, 2016, 17 (12) :1697-1708

[4] Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study [J].

Andre, Thierry ;

Tougeron, David ;

Piessen, Guillaume ;

de la Fouchardiere, Christelle ;

Louvet, Christophe ;

Adenis, Antoine ;

Jary, Marine ;

Tournigand, Christophe ;

Aparicio, Thomas ;

Desrame, Jerome ;

Lievre, Astrid ;

Garcia-Larnicol, Marie-Line ;

Pudlarz, Thomas ;

Cohen, Romain ;

Memmi, Salome ;

Vernerey, Dewi ;

Henriques, Julie ;

Lefevre, Jeremie H. ;

Svrcek, Magali .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) :255-+

[5] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[6] Commentary on: "Systematic assessment of complications after robotic-assisted total versus distal gastrectomy for advanced gastric cancer: A retrospective propensity score-matched study using Clavien-Dindo classification" [J].

Augustin, Goran .

INTERNATIONAL JOURNAL OF SURGERY, 2019, 72 :58-58

[7] Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].

Becker, K ;

Mueller, JD ;

Schulmacher, C ;

Ott, K ;

Fink, U ;

Busch, R ;

Böttcher, K ;

Siewert, JR ;

Höfler, H .

CANCER, 2003, 98 (07) :1521-1530

[8] Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials [J].

Chao, Joseph ;

Fuchs, Charles S. ;

Shitara, Kohei ;

Tabernero, Josep ;

Muro, Kei ;

Van Cutsem, Eric ;

Bang, Yung-Jue ;

De Vita, Ferdinando ;

Landers, Gregory ;

Yen, Chia-Jui ;

Chau, Ian ;

Elme, Anneli ;

Lee, Jeeyun ;

Ozguroglu, Mustafa ;

Catenacci, Daniel ;

Yoon, Harry H. ;

Chen, Erluo ;

Adelberg, David ;

Shih, Chie-Schin ;

Shah, Sukrut ;

Bhagia, Pooja ;

Wainberg, Zev A. .

JAMA ONCOLOGY, 2021, 7 (06) :895-902

[9] PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].

Curran, Michael A. ;

Montalvo, Welby ;

Yagita, Hideo ;

Allison, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280

[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

← 1 2 3 4 5 →